New Technology in Mass spectrometry (MS) to facilitate immunotherapy and personalized medicine development

The emergence of new genomics technologies has been a key driver towards the development of personalized medicine to deliver a treatment tailored to the patient’s needs.

Mass spectrometry (MS) offe…

Domain Therapeutics, Université de Montréal, IRICoR and McGill University extend licensing and partnership agreement on G Protein-Coupled Receptor biosensor technology

Domain Therapeutics will get exclusive access to a new set of more powerful biosensors that will facilitate profiling of more effective and safer drug candidates
Strasbourg (France) and Montreal (Can…

Visit of a Boston’s delegation at IRIC

On September 20, 2016, as part of an economic mission organized by the Ministry of Economy, Science and Innovation, BioQuébec and Montréal International, IRIC…

Mrs. Johane Boucher-Champagne is appointed to IRIC’s Board of Directors

The Executive Committee of Université de Montréal nominated Mrs. Johane Boucher-Champagne for a three-year term as member of the Board of Directors of IRIC…

A project on a specific form of pediatric leukemia receives a substantial grant

Trang Hoang, Principal Investigator, Hematopoiesis and Leukemia research unit at the Institute for Research in IRIC, received a substantial grant from…

Eight researchers from IRIC were awarded a grant from the CIHR

This past July, the Canadian Institutes of Health Research (CIHR) unveiled the grant winners for research projects spearheaded by scientists from across the country. Eight researchers from IRIC…

A new technology to monitor G protein-coupled receptor (GPCR) trafficking

Upon stimulation with angiotensin II, AT1 receptors translocate to the endosome and generate an eb-BRET signal by associating with the endosomal marker rGFP-FYVE…

Nadine Beauger at the Helm of IRICoR

Nadine Beauger becomes the new Chief Executive Officer of the Institute for Research in Immunology and Cancer — Commercialization of Research (IRICoR). She is taking over the role from Michel Bouvier …

Matthew J. Smith joins IRIC as Principal Investigator

The Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal (UdeM) is pleased to announce the arrival of Matthew J. Smith as principal investigator in the Cancer Signaling…

Health Canada allows clinical trials for the molecule UM171

Dr. Guy Sauvageau and Anne Marinier

Health Canada has allowed the first clinical trial phases for the transplantation of stem c…

Dr. Guy Sauvageau the winner of the Léo-Pariseau Award from ACFAS

Dr. Guy Sauvageau, Principal Investigator at IRIC the Université de Montréal, professor on the Faculty of Medicine

Dr. Guy…

North American premiere: acquisition at IRIC of a powerful microscope to uncover the secrets of cell division

IRIC has just acquired a powerful microscope in order to study complex cellular phenomena in the tissues of living organisms and in primary cancerous tumors, with the aim of better understanding cell division and thereby accelerating the discovery of new cancer drugs…

Together works better: the Cancer Research Society and IRIC join forces to promote cancer research

IRIC and the Cancer Research Society are joining forces to promote cancer research in the framework of a poster camp…

IRIC students distinguished themselves from the Cole Foundation

Several students from IRIC have distinguished themselves from the Cole Foundation, receiving a scholarship for their research on cancer…

Vincent Archambault winner of the 2015 GE Healthcare New Investigator Award

Vincent Archambault, Principal Investigator at IRIC…

World breakthrough by IRIC team of Dr. Guy Sauvageau voted Québec Science Discovery of the Year

The team of Dr. Guy Sauvageau made an unprecedented breakthrough thanks to the discovery of a new molecule that expands stem cells from umbilical cord blood.

Cyclenium Pharma and IRICoR Announce Collaborative Research Agreement

Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the discovery and development of novel drug candidates based on proprietary macrocyclic chemistry and the Institute for Resear…

The new molecule UM171 for treating blood cancer selected as a discovery of the year by Québec Science

Fruit of the research of Dr. Guy Sauvageau’s team at IRIC